CAR-T cell therapy for severe GPA or MPA
Treatments studied
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Lungs & breathing, Skin clinical trials.
This trial tests a new CAR-T cell treatment (rapcabtagene autoleucel) for people with severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). It aims to see if this therapy can help control the disease by targeting certain immune cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a diagnosis of GPA or MPA confirmed by standard medical criteria.
- Your blood test must show ANCA antibodies, which are linked to these diseases.
- Your disease must be severe and active.
- You cannot have other autoimmune diseases that need treatment.
- Your major organs must be working well enough to handle the therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It's designed for people with certain autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome that are not controlled by standard treatments.
This trial tests a new treatment called CT1192 for a type of blood vessel inflammation called ANCA-associated vasculitis. It is for people whose standard treatments have not worked or whose disease has come back. The goal is to see if CT1192 is safe and helps control the disease.
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
This trial tests a new CAR T-cell therapy (CC-97540) for people with active ANCA vasculitis (GPA or MPA) that has not responded to or has returned after standard treatments. The goal is to see if this personalized cell therapy can calm the immune system and reduce disease activity.
This trial tests a new type of cell therapy called anti-CD19 CAR-T cells for people with active ANCA vasculitis that hasn't gotten better with standard medicines. The goal is to see if this treatment can calm the immune system and reduce disease activity.
Hear when a new ANCA Associated Vasculitis (AAV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.